These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 19190262)

  • 1. Engineered glucagon-like peptide-1-producing hepatocytes lower plasma glucose levels in mice.
    Riedel MJ; Lee CW; Kieffer TJ
    Am J Physiol Endocrinol Metab; 2009 Apr; 296(4):E936-44. PubMed ID: 19190262
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adenoviral vector-mediated glucagon-like peptide 1 gene therapy improves glucose homeostasis in Zucker diabetic fatty rats.
    Lee Y; Kwon MK; Kang ES; Park YM; Choi SH; Ahn CW; Kim KS; Park CW; Cha BS; Kim SW; Sung JK; Lee EJ; Lee HC
    J Gene Med; 2008 Mar; 10(3):260-8. PubMed ID: 18085721
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DsAAV8-mediated expression of glucagon-like peptide-1 in pancreatic beta-cells ameliorates streptozotocin-induced diabetes.
    Riedel MJ; Gaddy DF; Asadi A; Robbins PD; Kieffer TJ
    Gene Ther; 2010 Feb; 17(2):171-80. PubMed ID: 19865180
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gene therapy of diabetes using a novel GLP-1/IgG1-Fc fusion construct normalizes glucose levels in db/db mice.
    Kumar M; Hunag Y; Glinka Y; Prud'homme GJ; Wang Q
    Gene Ther; 2007 Jan; 14(2):162-72. PubMed ID: 16943856
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enteroinsular axis of db/db mice and efficacy of dipeptidyl peptidase IV inhibition.
    Nagakura T; Yasuda N; Yamazaki K; Ikuta H; Tanaka I
    Metabolism; 2003 Jan; 52(1):81-6. PubMed ID: 12524666
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Newly approved and promising antidiabetic agents.
    Combettes M; Kargar C
    Therapie; 2007; 62(4):293-310. PubMed ID: 17983555
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glucagon-like peptide 1 (GLP-1) in the treatment of diabetes.
    Nauck MA
    Horm Metab Res; 2004; 36(11-12):852-8. PubMed ID: 15655719
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the subchronic antidiabetic effects of DPP IV-resistant GIP and GLP-1 analogues in obese diabetic (ob/ob) mice.
    Irwin N; McClean PL; Flatt PR
    J Pept Sci; 2007 Jun; 13(6):400-5. PubMed ID: 17486662
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glucagon-like peptide-1 gene therapy in obese diabetic mice results in long-term cure of diabetes by improving insulin sensitivity and reducing hepatic gluconeogenesis.
    Lee YS; Shin S; Shigihara T; Hahm E; Liu MJ; Han J; Yoon JW; Jun HS
    Diabetes; 2007 Jun; 56(6):1671-9. PubMed ID: 17369525
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of therapeutic potentials of site-specific PEGylated glucagon-like peptide-1 isomers as a type 2 anti-diabetic treatment: Insulinotropic activity, glucose-stabilizing capability, and proteolytic stability.
    Youn YS; Chae SY; Lee S; Jeon JE; Shin HG; Lee KC
    Biochem Pharmacol; 2007 Jan; 73(1):84-93. PubMed ID: 17054919
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemoenzymatic synthesis of glycosylated glucagon-like peptide 1: effect of glycosylation on proteolytic resistance and in vivo blood glucose-lowering activity.
    Ueda T; Tomita K; Notsu Y; Ito T; Fumoto M; Takakura T; Nagatome H; Takimoto A; Mihara S; Togame H; Kawamoto K; Iwasaki T; Asakura K; Oshima T; Hanasaki K; Nishimura S; Kondo H
    J Am Chem Soc; 2009 May; 131(17):6237-45. PubMed ID: 19361194
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GLP-1 effect upon the GPI/IPG system in adipocytes and hepatocytes from diabetic rats.
    Márquez L; González N; Puente J; Valverde L; Villanueva-Peñacarrillo ML
    Diabetes Nutr Metab; 2001 Oct; 14(5):239-44. PubMed ID: 11806463
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preparation, characterization, and application of biotinylated and biotin-PEGylated glucagon-like peptide-1 analogues for enhanced oral delivery.
    Chae SY; Jin CH; Shin HJ; Youn YS; Lee S; Lee KC
    Bioconjug Chem; 2008 Jan; 19(1):334-41. PubMed ID: 18078308
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biologic actions and therapeutic potential of the proglucagon-derived peptides.
    Drucker DJ
    Nat Clin Pract Endocrinol Metab; 2005 Nov; 1(1):22-31. PubMed ID: 16929363
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incretin-based therapies: mimetics versus protease inhibitors.
    Brubaker PL
    Trends Endocrinol Metab; 2007 Aug; 18(6):240-5. PubMed ID: 17629492
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chronic administration of alogliptin, a novel, potent, and highly selective dipeptidyl peptidase-4 inhibitor, improves glycemic control and beta-cell function in obese diabetic ob/ob mice.
    Moritoh Y; Takeuchi K; Asakawa T; Kataoka O; Odaka H
    Eur J Pharmacol; 2008 Jul; 588(2-3):325-32. PubMed ID: 18499100
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GLP-1 C-terminal structures affect its blood glucose lowering-function.
    Li Y; Shi C; Lv Q; Zhang H; Li B; Bian G; Huang Q; Zhang W; Xue X; Ren X; Gao H; Sun C; Wang J; Zhang M
    J Pept Sci; 2008 Jul; 14(7):777-85. PubMed ID: 18200618
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glucagon-like peptide 1(GLP-1) in biology and pathology.
    Meier JJ; Nauck MA
    Diabetes Metab Res Rev; 2005; 21(2):91-117. PubMed ID: 15759282
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of dysregulated glucagon secretion in type 2 diabetes.
    D'Alessio D
    Diabetes Obes Metab; 2011 Oct; 13 Suppl 1():126-32. PubMed ID: 21824266
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Function of a long-term, GLP-1-treated, insulin-secreting cell line is improved by preventing DPP IV-mediated degradation of GLP-1.
    Green BD; Liu HK; McCluskey JT; Duffy NA; O'Harte FP; McClenaghan NH; Flatt PR
    Diabetes Obes Metab; 2005 Sep; 7(5):563-9. PubMed ID: 16050949
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.